Be used for the treatment of the preparation of people's antibody of TNF-α associated conditions

Be used for the treatment of the preparation of people's antibody of TNF-α associated conditions

  • CN 102,078,608 B
  • Filed: 08/15/2003
  • Issued: 04/13/2016
  • Est. Priority Date: 08/16/2002
  • Status: Active Grant
First Claim
Patent Images

1. a liquid aqueous pharmaceutical preparation, it comprises:

  • 50mg/ml human IgG1 Tumor necrosis factorα

    (TNF α

    ) antibody D2E7;

    Concentration for mannitol is first osmotic pressure regulator of 10-14mg/ml;

    Concentration for sodium chloride is second osmotic pressure regulator of 6.0-6.4mg/ml;

    Comprise citric acid, sodium citrate, two hypophosphite monohydrate disodium hydrogens, the citrate of two hypophosphite monohydrate sodium dihydrogens and phosphate buffer system;

    Concentration for anhydrous sorbitol polyoxyethylene (20) oleic acid ester is the detergent of 0.5-5mg/ml;

    For the solvent of water;

    WithFor the pH adjusting agent of NaOH;

    Wherein said preparation has the pH of 4.5-6.

View all claims
    ×
    ×

    Thank you for your feedback

    ×
    ×